參考文獻:(上下滑動查看)
[1] Wang Y, Zhao X, Lin J, et al. CHANCEinvestigators.Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy ofClopidogrel for Risk Reduction Among Patients With Minor Stroke or TransientIschemic Attack[J].JAMA, 2016,316(1):70-78.
[2] Ahrens I, Schwarz M,Peter K, et al. Therapeutic Inhibitors of Platelet Aggregation – from Aspirinto Integrin Blockers[J]. Transfus Med Hemother, 2007,34(1):44–54.
[3] 單清,孫安修.質子泵抑制劑預防性應用專家共識(2018)[J].中國醫師雜誌,2018,20(12):1775-1781.
[4] 中華醫學會心血管病學會.2014抗血小板藥物治療反應多樣性臨床檢測和處理的中國專家建議[J].臨床薈萃,2015,30(4):366.
[5] Scott SA, Sanqkuhl K, Stein CM, etal. Clinical PharmacogeneticsImplementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy:2013 update [J]. Clinicalpharmacology and therapeutics, 2013,94(3):317-323.
[6] 世界華人檢驗與病理醫師協會,中國醫師協會檢驗醫師分會心血管檢驗醫學專業委員會.血小板功能檢測在急性冠脈症候群患者抗血小板治療中的應用專家共識[J].中華醫學雜誌,2018,98(22):1743-1751.